Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) EBIT (2023 - 2025)

Zenas BioPharma has reported EBIT over the past 3 years, most recently at $65.7 million for Q4 2025.

  • Quarterly results put EBIT at $65.7 million for Q4 2025, up 218.17% from a year ago — trailing twelve months through Dec 2025 was -$79.3 million (up 51.59% YoY), and the annual figure for FY2025 was -$79.3 million, up 51.59%.
  • EBIT for Q4 2025 was $65.7 million at Zenas BioPharma, up from -$52.6 million in the prior quarter.
  • Over the last five years, EBIT for ZBIO hit a ceiling of $65.7 million in Q4 2025 and a floor of -$55.6 million in Q4 2024.
  • Median EBIT over the past 3 years was -$38.5 million (2024), compared with a mean of -$23.2 million.
  • Biggest five-year swings in EBIT: plummeted 215.05% in 2024 and later skyrocketed 218.17% in 2025.
  • Zenas BioPharma's EBIT stood at -$24.8 million in 2023, then crashed by 124.48% to -$55.6 million in 2024, then skyrocketed by 218.17% to $65.7 million in 2025.
  • The last three reported values for EBIT were $65.7 million (Q4 2025), -$52.6 million (Q3 2025), and -$55.2 million (Q2 2025) per Business Quant data.